Literature DB >> 18508657

The different functions of Stat5 and chromatin alteration through Stat5 proteins.

Jan-Wilhelm Kornfeld1, Florian Grebien, Marc A Kerenyi, Katrin Friedbichler, Boris Kovacic, Barbara Zankl, Andrea Hoelbl, Harini Nivarti, Hartmut Beug, Veronika Sexl, Mathias Muller, Lukas Kenner, Ernst W Mullner, Fabrice Gouilleux, Richard Moriggl.   

Abstract

Stat5 proteins modulate gene transcription upon cytokine- and growth factor action. Stat5a and Stat5b proteins alone are weak activators of transcription. They can modify chromatin organization through oligomerization and they act predominantly in co-operation and interaction with other proteins. The conservative view of exclusively nuclear functions of Stat5 was challenged by the observation of additional Stat5 effects in the cytoplasm, resulting in activation of the PI3K-Akt pathway. We summarize biological consequences of mutations in conserved domains of Stat5 or of deletions in the N- or C-terminal domains with impact on target gene transcription. Formation of higher-order oligomers is dramatically changed upon amino- or carboxyterminal deletions in Stat5 proteins. Mutations in or deletion of the Stat5 N-terminus leads to diminished leukemogenic potential of oncogenic Stat5, probably due to the inability to form Stat5 tetramers. The Stat5 N-terminal domain prevents persistent activation and can act as a DNA-docking platform for the glucocorticoid receptor (GR). The corresponding protocols should facilitate follow-up studies on Stat5 proteins and their contribution to normal physiological versus pathological processes through differential chromatin binding.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18508657      PMCID: PMC2976847          DOI: 10.2741/3151

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  103 in total

1.  Expression of a tyrosine phosphorylated, DNA binding Stat3beta dimer in bacteria.

Authors:  S Becker; G L Corthals; R Aebersold; B Groner; C W Müller
Journal:  FEBS Lett       Date:  1998-12-11       Impact factor: 4.124

2.  Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction.

Authors:  M Socolovsky; A E Fallon; S Wang; C Brugnara; H F Lodish
Journal:  Cell       Date:  1999-07-23       Impact factor: 41.582

3.  Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells.

Authors:  R Moriggl; D J Topham; S Teglund; V Sexl; C McKay; D Wang; A Hoffmeyer; J van Deursen; M Y Sangster; K D Bunting; G C Grosveld; J N Ihle
Journal:  Immunity       Date:  1999-02       Impact factor: 31.745

4.  Stat5 activation is uniquely associated with cytokine signaling in peripheral T cells.

Authors:  R Moriggl; V Sexl; R Piekorz; D Topham; J N Ihle
Journal:  Immunity       Date:  1999-08       Impact factor: 31.745

5.  The significance of tetramerization in promoter recruitment by Stat5.

Authors:  S John; U Vinkemeier; E Soldaini; J E Darnell; W J Leonard
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

6.  Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNgamma-mediated signaling.

Authors:  M Zhu; S John; M Berg; W J Leonard
Journal:  Cell       Date:  1999-01-08       Impact factor: 41.582

7.  p300/CREB-binding protein enhances the prolactin-mediated transcriptional induction through direct interaction with the transactivation domain of Stat5, but does not participate in the Stat5-mediated suppression of the glucocorticoid response.

Authors:  E Pfitzner; R Jähne; M Wissler; E Stoecklin; B Groner
Journal:  Mol Endocrinol       Date:  1998-10

8.  A sequence of the CIS gene promoter interacts preferentially with two associated STAT5A dimers: a distinct biochemical difference between STAT5A and STAT5B.

Authors:  F Verdier; R Rabionet; F Gouilleux; C Beisenherz-Huss; P Varlet; O Muller; P Mayeux; C Lacombe; S Gisselbrecht; S Chretien
Journal:  Mol Cell Biol       Date:  1998-10       Impact factor: 4.272

9.  Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation.

Authors:  M Onishi; T Nosaka; K Misawa; A L Mui; D Gorman; M McMahon; A Miyajima; T Kitamura
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

10.  Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity.

Authors:  K Imada; E T Bloom; H Nakajima; J A Horvath-Arcidiacono; G B Udy; H W Davey; W J Leonard
Journal:  J Exp Med       Date:  1998-12-07       Impact factor: 14.307

View more
  22 in total

1.  Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation.

Authors:  Katrin Friedbichler; Marc A Kerenyi; Boris Kovacic; Geqiang Li; Andrea Hoelbl; Saliha Yahiaoui; Veronika Sexl; Ernst W Müllner; Sabine Fajmann; Sabine Cerny-Reiterer; Peter Valent; Hartmut Beug; Fabrice Gouilleux; Kevin D Bunting; Richard Moriggl
Journal:  Blood       Date:  2010-05-27       Impact factor: 22.113

2.  Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis.

Authors:  J A Cutler; R Tahir; S K Sreenivasamurthy; C Mitchell; S Renuse; R S Nirujogi; A H Patil; M Heydarian; X Wong; X Wu; T-C Huang; M-S Kim; K L Reddy; A Pandey
Journal:  Leukemia       Date:  2017-02-17       Impact factor: 11.528

3.  STAT5 N-domain deleted isoforms are naturally occurring hypomorphs partially rescued in hematopoiesis by transgenic Bcl-2 expression.

Authors:  Zhengqi Wang; Geqiang Li; Kevin D Bunting
Journal:  Am J Blood Res       Date:  2014-09-05

4.  Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.

Authors:  Christoph Walz; Wesam Ahmed; Katherine Lazarides; Monica Betancur; Nihal Patel; Lothar Hennighausen; Virginia M Zaleskas; Richard A Van Etten
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

5.  GH/STAT5 signaling during the growth period in livers of mice overexpressing GH.

Authors:  Carolina S Martinez; Verónica G Piazza; María E Díaz; Ravneet K Boparai; Oge Arum; María C Ramírez; Lorena González; Damasia Becú-Villalobos; Andrzej Bartke; Daniel Turyn; Johanna G Miquet; Ana I Sotelo
Journal:  J Mol Endocrinol       Date:  2015-02-17       Impact factor: 5.098

6.  Control of CD8 T cell proliferation and terminal differentiation by active STAT5 and CDKN2A/CDKN2B.

Authors:  Magali Grange; Marilyn Giordano; Amandine Mas; Romain Roncagalli; Guylène Firaguay; Jacques A Nunes; Jacques Ghysdael; Anne-Marie Schmitt-Verhulst; Nathalie Auphan-Anezin
Journal:  Immunology       Date:  2015-06-15       Impact factor: 7.397

7.  Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma.

Authors:  Natini Jinawath; Chanont Vasoontara; Artit Jinawath; Xueping Fang; Kejia Zhao; Kai-Lee Yap; Tong Guo; Cheng S Lee; Weijie Wang; Brian M Balgley; Ben Davidson; Tian-Li Wang; Ie-Ming Shih
Journal:  PLoS One       Date:  2010-06-18       Impact factor: 3.240

8.  Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia.

Authors:  Andrea Hoelbl; Christian Schuster; Boris Kovacic; Bingmei Zhu; Mark Wickre; Maria A Hoelzl; Sabine Fajmann; Florian Grebien; Wolfgang Warsch; Gabriele Stengl; Lothar Hennighausen; Valeria Poli; Hartmut Beug; Richard Moriggl; Veronika Sexl
Journal:  EMBO Mol Med       Date:  2010-03       Impact factor: 12.137

9.  Altered gene expression patterns during the initiation and promotion stages of neonatally diethylstilbestrol-induced hyperplasia/dysplasia/neoplasia in the hamster uterus.

Authors:  William J Hendry; Hussam Y Hariri; Imala D Alwis; Sumedha S Gunewardena; Isabel R Hendry
Journal:  Reprod Toxicol       Date:  2014-09-19       Impact factor: 3.143

10.  Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway.

Authors:  Harald Schnidar; Markus Eberl; Stefan Klingler; Doris Mangelberger; Maria Kasper; Cornelia Hauser-Kronberger; Gerhard Regl; Renate Kroismayr; Richard Moriggl; Maria Sibilia; Fritz Aberger
Journal:  Cancer Res       Date:  2009-02-03       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.